OTC · Biotechnology

Kintor Pharmaceutical Limited (KNTPF) Stock

$0.23 -0.20% OTC: KNTPF Healthcare

Kintor Pharmaceutical Limited is a clinical-stage biotechnology firm dedicated to the development and commercialization of a diverse pipeline of small molecule and biologic treatments. Its primary focus is on addressing androgen-receptor-related conditions where current medical options are lacking, serving patients both within the People's Republic of China and globally.

Valuation

MetricValue
Price$0.23
Market Cap$107.85M
P/E Ratio-3.33
P/B Ratio3.71
P/S Ratio21.04
EPS (TTM)$-0.43
52-Week High$0.57
52-Week Low$0.18
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-98.57%
ROA-57.63%
ROCE-93.65%
Gross Margin24.60%
Operating Margin-611.29%
Net Margin-601.18%
Debt/Equity0.47
Current Ratio0.43

Annual Financials (USD)

Metric20212022202320242025
Revenue$34.0M$0$0$5.0M$32.0M
Operating Profit$-840.0M$-945.0M$-152.0M$-145.0M$-197.0M
Net Profit$-842.0M$-954.0M$-1.1B$-155.0M$-195.0M
EPS$-2.36$-2.53$-2.47$-0.36$-0.43
Op Margin-2452.8%——-2891.4%-619.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.1B$2.1B$869.0M$515.0M$341.0M
Total Liabilities$413.0M$560.0M$411.0M$221.0M$158.0M
Cash$1.0M$1.0M$445.0M$147.0M$35.0M
Borrowings$160.0M$286.0M$254.0M$133.0M$87.0M

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$-1.0M$-388.0M$-199.0M$-170.0M
Investing Cash Flow$0$0$1.0M$18.0M$14.0M
Financing Cash Flow$-888.0M$-820.0M$-5.0M$-5.0M$-1.0M
Net Cash Flow$0$0$-420.0M$-297.0M$-115.0M
Free Cash Flow$-1.0M$-1.0M$-390.0M$-201.0M$-170.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.27
EV / EBITDA-5.26
FCF Yield-25.50%
Quick Ratio0.34
Interest Coverage-52.00
Return 1Y29.65%
Return 3Y-49.04%
Return 5Y—

Ownership

Insiders Held16.98%
Institutions Held9.91%
Institutions Float Held11.94%
Institutional HolderSharesReport Date
SPDR INDEX SHARES Fd.S-State Street SPDR S&P Emerging Markets Small Ca323,0002026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AURXNuo Therapeutics, Inc. $1.00 +11.11% -20.00 $48.41M 0.00%
HOFBFHofseth BioCare ASA $0.17 +0.00% -3.90 $68.47M 0.00%
IPHYFInnate Pharma S.A. $1.65 +0.00% -2.84 $154.94M 0.00%
IUGNFImugene Limited $0.10 +0.00% -0.40 $41.60M 0.00%
MSCLFSatellos Bioscience Inc. $6.25 +11.81% -1.75 $96.62M 0.00%

About Kintor Pharmaceutical Limited

Kintor Pharmaceutical Limited is a clinical-stage biotechnology firm dedicated to the development and commercialization of a diverse pipeline of small molecule and biologic treatments. Its primary focus is on addressing androgen-receptor-related conditions where current medical options are lacking, serving patients both within the People's Republic of China and globally. The company's innovative pipeline features several key candidates, such as Proxalutamide, a next-generation androgen receptor (AR) antagonist currently being investigated for metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Another notable compound is Pyrilutamide, also an AR antagonist, designed to treat androgenetic alopecia (AGA) and acne vulgaris. Kintor also has an ALK-1 antibody in its portfolio, aimed at metastatic hepatocellular carcinoma (HCC) and various other solid tumors. Additionally, GT20029, a topical AR-PROTAC compound, is under development for AGA and acne vulgaris. A dual-target antibody, PD-L1/TGF-ß, is being explored for its potential in treating non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Further contributing to its diverse offerings is Detorsertib, intended for metastatic solid tumors including breast, prostate, and HCC. Finally, a Hedgehog/SMO Inhibitor, which targets the hedgehog signal transduction pathway, is being developed for blood cancer and basal-cell carcinoma. Established in 2009, Kintor Pharmaceutical Limited maintains its headquarters in Suzhou, People's Republic of China.

Kintor Pharmaceutical Limited is headquartered in CN.

Kintor Pharmaceutical Limited (KNTPF) stock trades at $0.23 with a market capitalization of $107.85M. The stock is valued at a price-to-earnings (P/E) ratio of -3.33, price-to-book of 3.71, price-to-sales of 21.04. Over the past 52 weeks the stock has ranged between $0.18 and $0.57, and currently trades 59.6% below its 52-week high.

On profitability, Kintor Pharmaceutical Limited generates a return on equity (ROE) of -98.57%, return on capital employed of -93.65%, an operating margin of -611.29%, a net profit margin of -601.18%.

Official website: www.kintor.com.cn

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides